For decades, Medicare explicitly excluded anti-obesity drugs. That's changing. The BALANCE Model announced in December 2025 opens GLP-1 coverage for millions of Medicare beneficiaries — and Medicaid coverage is expanding state by state. Here's the full picture.
Disclosure: Some links on this page are affiliate links. Policy information verified as of May 2026 — government programs change frequently.
Medicare: The BALANCE Model
CMS (Centers for Medicare & Medicaid Services) announced the BALANCE Model (Building Access to Long-term Anti-Obesity Needs through Coverage Enhancement) in December 2025. This is the most significant expansion of Medicare obesity treatment coverage in the program's history.
What's Covered
| Detail | Current Terms |
|---|---|
| Eligible medication | Wegovy (semaglutide) — covered for cardiovascular risk reduction |
| Patient criteria | Established cardiovascular disease + obesity or overweight |
| Monthly cost cap | ~$50/month |
| Current phase | Limited rollout in 2026 |
| Full Part D coverage | Expected January 2027 |
The BALANCE Model uses Wegovy's cardiovascular indication (based on the SELECT trial, which showed a 20% reduction in major cardiovascular events) to justify coverage — not the weight loss indication. This is the regulatory pathway that made Medicare coverage possible despite the longstanding anti-obesity drug exclusion.
Who Qualifies
To qualify under the BALANCE Model, you need:
- Medicare Part D coverage
- Established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease)
- BMI ≥27 (overweight or obese)
- A prescribing provider who documents the cardiovascular indication
What's Not Covered (Yet)
The BALANCE Model does not currently cover:
- GLP-1s prescribed solely for weight loss without cardiovascular disease
- Tirzepatide (Mounjaro/Zepbound) — only semaglutide (Wegovy) is included
- Compounded GLP-1 medications
Medicare Part D: What's Coming in 2027
Full Part D anti-obesity medication coverage is expected to begin January 2027. This would expand access beyond the cardiovascular indication, potentially covering GLP-1s for weight management more broadly. Details are still being finalized — check Medicare.gov for updates.
Medicaid Coverage: State by State
Medicaid coverage of GLP-1 medications for weight loss varies dramatically by state. There is no federal mandate requiring states to cover anti-obesity medications.
| Coverage Status | What It Means | Examples |
|---|---|---|
| Full AOM coverage | Covers GLP-1s for weight management with PA | Growing number of states |
| Diabetes only | Covers Ozempic/Mounjaro for T2D, not for weight loss | Many states |
| Excluded | Anti-obesity drugs explicitly excluded from formulary | Some states |
Medicaid formularies change frequently. Contact your state Medicaid office or managed care plan directly to verify current GLP-1 coverage for weight management. State mandate legislation (like California's AB-575) may be expanding coverage in your area.
What Government-Insured Patients Can't Do
Federal law creates specific limitations for Medicare and Medicaid beneficiaries:
- No manufacturer copay cards — Novo Nordisk and Eli Lilly savings programs are off-limits for government-insured patients
- Limited formulary options — the specific drugs and doses covered are determined by the plan formulary
- Prior authorization required — even under BALANCE, expect PA requirements
Options Outside Government Insurance
If Medicare or Medicaid doesn't cover GLP-1s for your situation, cash-pay compounded programs remain available. These operate entirely outside the insurance system:
Timeline: What's Coming
| When | What | Impact |
|---|---|---|
| 2026 | BALANCE Model limited rollout | First Medicare GLP-1 coverage for CV risk patients |
| Jan 2027 | Full Part D AOM coverage expected | Broader Medicare access beyond CV indication |
| 2026-2027 | State Medicaid expansions | More states adding AOM coverage |
| 2031+ | Semaglutide patent expiration | Generic sema could dramatically lower costs for all payers |
- Medicare BALANCE Model: first-ever Medicare GLP-1 coverage for patients with CV disease + obesity
- Monthly cost cap ~$50 under BALANCE; full Part D coverage expected January 2027
- Medicaid varies by state — no federal mandate for AOM coverage; check your state
- Government-insured patients cannot use manufacturer savings cards
- Cash-pay compounded programs ($130–$199/mo) operate outside government insurance entirely
- 2031 semaglutide patent expiration could reshape pricing for all payers
Government insurance coverage changes frequently. Verify current terms with Medicare.gov, your state Medicaid office, or your specific plan. This is not insurance or medical advice.